VBL Therapeutics announces peer-reviewed publication of positive results of pre-specified interim analysis of OVAL, a phase III registration enabling study of VB 111 in ovarian cancer.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest